Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Dojolvi is the only approved therapy for this rare, life-threatening metabolic disorder Dojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
4 Underpriced Healthcare Stocks That Wall Street Adores
11:46am, Thursday, 19'th Aug 2021
A drug maker, two insurers, and a medical-device company pass our screen of healthcare concerns with high analysts ratings and upside potential.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 17'th Aug 2021
NOVATO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference
08:30am, Wednesday, 04'th Aug 2021
NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
02:30pm, Tuesday, 03'rd Aug 2021
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2021 Results - Earnings Call Transcript
12:28am, Tuesday, 03'rd Aug 2021
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2021 Results - Earnings Call Transcript
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
07:04pm, Monday, 02'nd Aug 2021
Ultragenyx (RARE) delivered earnings and revenue surprises of -13.28% and 4.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx Pharmaceutical: Q2 Earnings Insights
04:31pm, Monday, 02'nd Aug 2021
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 61.61% year over year to (
Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update
04:05pm, Monday, 02'nd Aug 2021
Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million
Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update
05:00pm, Tuesday, 27'th Jul 2021
NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-ra
Ultragenyx: Prices Are Attractively Low
08:31am, Friday, 23'rd Jul 2021
Ultragenyx targets rare diseases with high unmet need.
TOKYO--(BUSINESS WIRE)--An additional option is now available in the treatment of XLH, a rare metabolic bone disease
Nvidia, SeaWorld, Wells Fargo and More Thursday Afternoon Analyst Calls
11:46am, Thursday, 15'th Jul 2021
With the trading day about halfway over, the major averages had pulled back slightly.
MADRID, Spain, July 13, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ul
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
08:30am, Wednesday, 30'th Jun 2021
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
